Back to User profile » Dr Anthony R Mato
Papers published by Dr Anthony R Mato:
Review
Zanubrutinib (BGB-3111), a Second-Generation Selective Covalent Inhibitor of Bruton’s Tyrosine Kinase and Its Utility in Treating Chronic Lymphocytic Leukemia
Rhodes JM, Mato AR
Drug Design, Development and Therapy 2021, 15:919-926
Published Date: 2 March 2021
Original Research
The Impact of Age on Survival in CLL Patients Receiving Ibrutinib as Initial Therapy
Ujjani C, Mato A, Hill BT, Allan JN, Lansigan E, Jacobs R, Tuncer H, Pagel J, Brander D, Cheson B, Barr P, Roeker LE, Pu J, Shah NN, Goy A, Schuster SJ, Lamanna N, Sehgal A, Tam CS, Shadman M
Blood and Lymphatic Cancer: Targets and Therapy 2020, 10:1-5
Published Date: 24 August 2020
Review
Acalabrutinib and Its Therapeutic Potential in the Treatment of Chronic Lymphocytic Leukemia: A Short Review on Emerging Data
Isaac K, Mato AR
Cancer Management and Research 2020, 12:2079-2085
Published Date: 19 March 2020